Shortly after the G7 Research Ministers Conference, which Germany chaired in October of this year, the Ministry announced a call for a second PDP founding round, for which 50 million euros is to be available for 2016 to 2021. Although we had advocated for a sum of 100 million euros for four years, this still represents almost a doubling of what was available in the first round of funding.

What is special about PDPs?
PDPs are international non-profit organisations that develop drugs, vaccines and diagnostics for PRNDs in co-operation with pharmaceutical companies and public and academic research institutions. They have already been in existence for more than 20 years, and their advantage is that their activities are output-oriented. Allocation of public research funding is justified because they help introducing a product on the market at a low price, which makes it much easier to get that product to the people who need it.